DiaMedica Therapeutics Inc. (DMAC) vs Sight Sciences, Inc. (SGHT)
A side-by-side comparison of DiaMedica Therapeutics Inc. and Sight Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DMAC
DiaMedica Therapeutics Inc.
$8.13HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SGHT
Sight Sciences, Inc.
$8.56HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — DMAC vs SGHT
growth of $100 · dividends reinvested · last 5yDMAC +112.1% (+16.2%/yr)SGHT -73.4% (-23.3%/yr)DMAC compounded faster over this window
Log scale — wide-divergence pair
DMAC SGHT
DMAC vs SGHT: by the numbers
- •SGHT is the larger company ($466M vs $438M market cap).
- •Both run net losses; DMAC's is the smaller (0.00% vs -35.69% net margin).
Metrics side by side
Valuation
| Metric | DMAC | SGHT |
|---|---|---|
| P/S ratio | N/A | 5.59 |
| P/B ratio | 11.43 | 8.81 |
Profitability
| Metric | DMAC | SGHT |
|---|---|---|
| Gross margin | 0.00% | 87.96% |
| Operating margin | 0.00% | -47.95% |
| Net margin | 0.00% | -35.69% |
| ROE | -97.92% | -56.26% |
| ROIC | -100.87% | -29.50% |
Growth (annualized)
| Metric | DMAC | SGHT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 16.53% |
| Total return CAGR (5Y) | 16.41% | -18.69% |
Frequently asked
- How have DMAC and SGHT total returns compared?
- Over the past 5 years, DMAC delivered 16.41% and SGHT delivered -18.69% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
DiaMedica Therapeutics ROESight Sciences ROEDiaMedica Therapeutics operating marginSight Sciences operating marginDiaMedica Therapeutics revenue growthSight Sciences revenue growthDiaMedica Therapeutics free cash flowSight Sciences free cash flow
DiaMedica Therapeutics & Sight Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.